San Diego-dependent Viking Therapeutics marked itself as a serious competitor while in the weight loss drug market in February soon after revealing promising knowledge from a mid-phase demo of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when given being a weekly injection and in March the company